General (130) Partnerships (24) New Products (8) Acquisitions (6) Financials (1) New Technologies (1)
Pharma and Biotech (146) Corporate (13) Bioscience (8)
2020 (19) 2019 (32) 2018 (25) 2017 (23) 2016 (28) 2015 (12) 2014 (7)
Showing 1‐20 of 146
results per page
04 Aug 2020
Lonza Expands Microbial Capacity and Extends Long-term Partnership with Servier for L-asparaginase API Manufacturing
New mid-scale microbial facility to support Servier with active pharmaceutical ingredient (API) for acute lymphoblastic leukemia (ALL)...
27 Jul 2020
Lonza's Ibex Dedicate to Support the Commercial Manufacture of Kodiak’s KSI-301 - an Antibody Biopolymer Conjugate for Retinal Diseases
•  Purpose-built bioconjugation facility in Lonza’s Ibex™ Dedicate Biopark to support the potential commercial launch of Kodiak's leading...
13 Jul 2020
Junshi Biosciences and Lonza Partner to Produce a Neutralizing Antibody Tackling COVID-19
Junshi Biosciences developing therapies for COVID-19 in collaboration with a number of global partnersJunshi Biosciences' first SARS-CoV-2...
08 Jul 2020
Lonza Establishes Center of Excellence for Integrated Dry Powder Inhaler Product Development Services
Lonza establishes a new Center of Excellence to leverage its core particle engineering expertise utilizing both particle size reduction and spray...
01 Jul 2020
Lonza Expands Particle Engineering Services
Lonza doubles the network jet-milling capacity for supporting development stage projects and expands the capabilities in specialized cGMP...
18 Jun 2020
Lonza’s New GSv9 TM Media and Feeds Maximize Yield and Batch-to-Batch Consistency to Support Recombinant Protein Production Scale-Up
GSv9™ is Lonza’s newly launched chemically defined media and feeds platform, specifically developed to enhance the performance of the GS Gene...
11 Jun 2020
Anthos Therapeutics Partners with Lonza to Develop and Manufacture Abelacimab (MAA868), a Unique Dual Factor XI / XIa inhibitor
The agreement furthers Anthos Therapeutics mission to develop Abelacimab for patients at risk of thrombotic events, which are currently underserved...
10 Jun 2020
Lonza and CELLINK Join Forces to Offer Complete 3D Cell Culture Workflows
Lonza has collaborated with CELLINK to offer a comprehensive 3-dimensional (3D) bioprinting solution designed to advance complete 3D cell culture...
29 May 2020
Surrozen and Lonza Announce Partnership for the Development and Manufacture of Surrozen’s Novel Wnt Activating Antibodies
Surrozen is developing first-in-class bi-specific antibodies that selectively stimulate tissue regenerationLonza to provide cell line development,...
18 May 2020
Moncef Slaoui to Step Down as Member of the Board of Directors of Lonza Group
Basel, Switzerland, 18 May 2020 – Dr Moncef Slaoui has decided to step down from his position as a member of the Lonza Group Board of Directors,...
12 May 2020
Noga Therapeutics and Lonza Announce Collaboration to Develop Autologous Lentiviral Gene Therapy on the Cocoon Platform
Collaboration between Noga Therapeutics and Lonza will leverage the innovative Cocoon® Platform for a novel primary immunodeficiency (PID)...
01 May 2020
Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus
•  Collaboration goal to enable manufacturing of up to 1 billion doses per year•  Technology transfer expected to begin in June 2020•  First...
23 Mar 2020
Lonza Launches New TheraPEAK™ SfAAV™ Medium to Boost and Optimize the Production of AAV in Sf9 Insect Cells
Lonza has launched a new medium to enhance and accelerate the production of Adeno Associated Virus (AAV) in Spodoptera Fuigiperda (Sf9) insect...
20 Mar 2020
Lonza Joins the MIT Industrial Liaison Program
Lonza joins the MIT Industrial Liaison Program (ILP), gaining access to a vibrant ecosystem of research and technology development.Lonza’s...
09 Mar 2020
Lonza Collaborates with Immunotherapy Leaders to Assess Point-of-Care Manufacturing for Cancer Cell Therapies
Research collaboration with leading research institutes and academic clinical centers Stanford University School of Medicine, Fred Hutchinson...
19 Feb 2020
Lonza confirms COVID-19 case at Singapore General Office
Basel, Switzerland, 19 February 2020 –A Singapore-based employee of Lonza is being treated for a confirmed cased of COVID-19 (Coronavirus).Albert...
28 Jan 2020
Lonza Supporting Rocket Pharma with Clinical Manufacturing of LAD-I for the Treatment of Leukocyte Adhesion Deficiency-I
Clinical manufacturing to be carried out at Lonza's Houston (TX), USA and Geleen, Netherlands cGMP manufacturing sites for supply in the USA and in...
10 Jan 2020
Indapta Therapeutics and Lonza Announce Strategic Partnership to Advance a Next-generation, Off-the-shelf, Allogeneic Immuno-oncology Therapy
•  Indapta developing first-in-class, proprietary cancer therapy based on a specific, potent variety of Natural Killer immune cells for use in...
09 Jan 2020
Lukas Schüpbach appointed CEO of Bacthera
Chr. Hansen and Lonza’s 50/50 joint venture for Live Biotherapeutic Products (LBP), Bacthera, announces Lukas Schüpbach as the company’s CEOBasel,...
19 Dec 2019
Lonza and Allevi Collaborate to Advance 3D Bioprinting
Collaboration brings technology and consumables together for bioprinting for research applications.Lonza brings a broad range of high-quality...
1 2 3 4 ... 8 >